140 related articles for article (PubMed ID: 38616248)
1. Triple-induction treatment for locally advanced non-small cell lung cancer: a case report of pathological complete response.
Werner RS; Lauk O; Tscherry G; Curioni-Fontecedro A; Höller S; Opitz I
J Cardiothorac Surg; 2024 Apr; 19(1):207. PubMed ID: 38616248
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
[TBL] [Abstract][Full Text] [Related]
4. Prospective trial of immuno(chemo)therapy before resection, definitive chemoradiotherapy or palliative therapy in patients with locally advanced or oligometastatic non-small cell lung cancer without a primary curative option.
Faehling M; Fallscheer S; Kramberg S; Sträter J; Eschmann S; Sätzler R; Heinzelmann F
Eur J Cancer; 2021 Oct; 156():175-186. PubMed ID: 34461420
[TBL] [Abstract][Full Text] [Related]
5. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer.
Lococo F; Cesario A; Margaritora S; Dall'Armi V; Mattei F; Romano R; Porziella V; Granone P
Eur J Cardiothorac Surg; 2013 Mar; 43(3):e71-81. PubMed ID: 23293319
[TBL] [Abstract][Full Text] [Related]
6. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
7. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
8. Results of neoadjuvant chemo(radio)therapy and resection for stage IIIA non-small cell lung cancer in The Netherlands.
Joosten PJM; Damhuis RAM; van Diessen JNA; de Langen JA; Belderbos JSA; Smit EF; Klomp HM; Veenhof AAFA; Hartemink KJ
Acta Oncol; 2020 Jul; 59(7):748-752. PubMed ID: 32347142
[No Abstract] [Full Text] [Related]
9. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
10. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer.
Pöttgen C; Gauler T; Bellendorf A; Guberina M; Bockisch A; Schwenzer N; Heinzelmann F; Cordes S; Schuler MH; Welter S; Stamatis G; Friedel G; Darwiche K; Jöckel KH; Eberhardt W; Stuschke M
J Clin Oncol; 2016 Jul; 34(21):2526-33. PubMed ID: 27247220
[TBL] [Abstract][Full Text] [Related]
11. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
13. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
15. Induction chemoradiotherapy and surgical resection for selected stage IIIB non-small-cell lung cancer.
Ichinose Y; Fukuyama Y; Asoh H; Ushijima C; Okamoto T; Ikeda J; Okamoto J; Sakai M
Ann Thorac Surg; 2003 Dec; 76(6):1810-4; discussion 1815. PubMed ID: 14667588
[TBL] [Abstract][Full Text] [Related]
16. [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results].
Schreiner W; Dudek W; Lettmaier S; Gavrychenkova S; Rieker R; Fietkau R; Sirbu H
Zentralbl Chir; 2016 Jun; 141(3):323-9. PubMed ID: 27035568
[TBL] [Abstract][Full Text] [Related]
17. Comparing the benefits of chemoradiotherapy and chemotherapy for resectable stage III A/N2 non-small cell lung cancer: a meta-analysis.
Chen Y; Peng X; Zhou Y; Xia K; Zhuang W
World J Surg Oncol; 2018 Jan; 16(1):8. PubMed ID: 29338734
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
[TBL] [Abstract][Full Text] [Related]
19. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
20. A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).
Nguyen NA; Isfahanian N; Pond G; Hanna W; Cutz JC; Wright J; Swaminath A; Shargall Y; Chow T; Wierzbicki M; Okawara G; Quan K; Finley C; Juergens R; Tsakiridis T
Clin Lung Cancer; 2017 Jul; 18(4):436-440.e1. PubMed ID: 28215851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
